EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections

Milo Gatti iD, Riccardo De Paola iD, Matteo Rinaldi iD, Cristiana Laici iD, Antonio Siniscalchi iD, Pierluigi Viale iD, Federico Pea iD

Transplant Infectious Disease · 2026

DOI: 10.1111/tid.70237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2026. Verfasst von Milo Gatti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Liver Transplantation, Anti-Bacterial Agents, beta-Lactams, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To assess the true prevalence and the risk factors of augmented renal clearance (ARC) in critical orthotopic liver transplant (OLT) recipients and its impact on early aggressive pharmacokinetic/pharmacodynamic (PK/PD) target non‐attainment of continuous infusion (CI) beta‐lactams.

Methods

OLT recipients without renal dysfunction and undergoing one or more measured creatinine clearance (mCLCr) assessments in the first 30 days posttransplant were retrospectively included. Reliability of three different eGFR formulas (Cockcroft–Gault, 2021, CKD‐EPI, and MDRD) in estimating mCLCr was tested. Univariate analyses compared the clinical features of ARC versus non‐ARC patients and the severity of the clinical conditions during ARC versus non‐ARC episodes in the whole cohort. In patients receiving CI beta‐lactam therapy, risk factors for early aggressive PK/PD target non‐attainment were investigated.

Results

Among 450 critical OLT recipients, 112 were included. The true prevalence of ARC was 23.2%. ARC versus non‐ARC patients were younger ( p = 0.003), had lower MELD score ( p = 0.001), received lower number of intraoperative blood transfusions ( p = 0.007), and had a lower need for venovenous bypass technique ( p = 0.024). ARC episodes occurred more frequently in patients having lower SOFA score ( p = 0.005) and lower median serum creatinine levels ( p < 0.001). None of the eGFR formulas properly estimated mCLCr. In the subset of 50 OLT recipients receiving 60 CI beta‐lactam treatment courses, ARC was the only factor associated with early aggressive PK/PD target non‐attainment ( p = 0.018).

Conclusions

ARC is a quite prevalent condition among critical OLT recipients, which may hinder early aggressive PK/PD target attainment when using standard beta‐lactams dosing regimens, regardless of delivery by CI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationAnti-Bacterial Agentsbeta-LactamsGram-Negative Bacterial InfectionsHumansRisk FactorsFemaleRetrospective StudiesMaleMiddle AgedPrevalenceGlomerular Filtration RateCritical IllnessCreatinineAgedAdult

Stichwörter der Autor:innen

augmented renal clearancebeta‐lactamscontinuous infusionearly aggressive PK/PD target attainmentmeasured creatinine clearanceorthotopic liver transplant

Substanzen

Anti-Bacterial Agentsbeta-LactamsCreatinine

Autor:innen und Institutionen

  • Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
  • Clinical Pharmacology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Specialization School of Clinical Pharmacology and Toxicology, Alma Mater Studiorum University of Bologna, Bologna, Italy.
  • Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Anesthesia and Intensive Care Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

ORCID-Profile: Milo Gatti, Riccardo De Paola, Matteo Rinaldi, Cristiana Laici, Antonio Siniscalchi, Pierluigi Viale, Federico Pea

Förderung

  • Italian Ministry of Health

Zitieren

APA

Gatti, M., De Paola, R., Rinaldi, M., Laici, C., Siniscalchi, A., Viale, P., & Pea, F. (2026). ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections. Transplant Infectious Disease. https://doi.org/10.1111/tid.70237

Vancouver

Gatti M, De Paola R, Rinaldi M, Laici C, Siniscalchi A, Viale P, et al. ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections. Transplant Infectious Disease. 2026. doi:10.1111/tid.70237

BibTeX
@article{Gatti2026,
  author = {Gatti, Milo and De Paola, Riccardo and Rinaldi, Matteo and Laici, Cristiana and Siniscalchi, Antonio and Viale, Pierluigi and Pea, Federico},
  title = {ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections},
  journal = {Transplant Infectious Disease},
  year = {2026},
  doi = {10.1111/tid.70237}
}
Kostenlos starten →